Dianthus Therapeutics (DNTH) Free Cash Flow (2017 - 2025)

Dianthus Therapeutics' Free Cash Flow history runs 9 years deep, the most recent figure standing at -$30.6 million for Q3 2025.

• In Q3 2025, Free Cash Flow fell 43.53% year-over-year to -$30.6 million; the TTM figure through Dec 2025 stood at -$82.2 million (down 4.94% YoY), while the FY2024 annual figure was -$78.3 million, down 111.75% from the prior year.
• Free Cash Flow for Q3 2025 stood at -$30.6 million, down from -$23.9 million in the prior quarter.
• The five-year high for Free Cash Flow was $16.4 million in Q3 2022, with the low at -$30.6 million in Q3 2025.
• The 5-year median for Free Cash Flow is -$15.0 million (2024), against an average of -$15.1 million.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow surged 214.9% in 2022, then plunged 206.08% in 2024.
• Dianthus Therapeutics' Free Cash Flow stood at -$15.7 million in 2021, then jumped by 43.46% to -$8.9 million in 2022, then slumped by 33.6% to -$11.9 million in 2023, then plunged by 131.58% to -$27.5 million in 2024, then fell by 11.23% to -$30.6 million in 2025.
• Business Quant data shows DNTH's Free Cash Flow at -$30.6 million in Q3 2025, -$23.9 million in Q2 2025, and -$27.7 million in Q1 2025.